Vertex Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About VRTX

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. 

CEO
Reshma Kewalramani
CEOReshma Kewalramani
Employees
6,100
Employees6,100
Headquarters
Boston, Massachusetts
HeadquartersBoston, Massachusetts
Founded
1989
Founded1989
Employees
6,100
Employees6,100

VRTX Key Statistics

Market cap
129.15B
Market cap129.15B
Price-Earnings ratio
-228.42
Price-Earnings ratio-228.42
Dividend yield
Dividend yield
Average volume
1.49M
Average volume1.49M
High today
$512.75
High today$512.75
Low today
$488.00
Low today$488.00
Open price
$493.66
Open price$493.66
Volume
1.70M
Volume1.70M
52 Week high
$519.88
52 Week high$519.88
52 Week low
$377.85
52 Week low$377.85

VRTX News

Benzinga 7d
Vertex Newly Approved Pain Treatment Lands Higher Cost Tier 3 Placement In UnitedHealth's Optum Rx Formularies

In January, the Food and Drug Administration (FDA) approved Vertex Pharmaceuticals Inc. VRTX Journavx, a non-opioid oral pain signal inhibitor for acute pain....

Vertex Newly Approved Pain Treatment Lands Higher Cost Tier 3 Placement In UnitedHealth's Optum Rx Formularies
Simply Wall St 7d
Vertex Pharmaceuticals (NasdaqGS:VRTX) Gains UK Approval For New Cystic Fibrosis Treatment

On March 7, 2025, announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in expan...

Vertex Pharmaceuticals (NasdaqGS:VRTX) Gains UK Approval For New Cystic Fibrosis Treatment

Analyst ratings

57%

of 35 ratings
Buy
57.1%
Hold
37.1%
Sell
5.7%
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.